Thang Trong Khong

Thang Trong Khong

Auto-generated profile, based on publicly available information

Thang Trong Khong

Department of Intensive Care Unit, Vinmec International Hospital, Vinmec Healthcare System, Ho Chi Minh City, Vietnam

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2026 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
TUNG PHI NGUYENTUNG PHI NGUYEN
TUNG PHI NGUYEN
TKThang Trong Khong
Thang Trong Khong
HVHoai Thi Thu Vu
Hoai Thi Thu Vu
NNNam Ngoc Phuong Nguyen
Nam Ngoc Phuong Nguyen
PHPhuong Khanh Nguyen Hoang
Phuong Khanh Nguyen Hoang
TTTuan Duc Tran
Tuan Duc Tran
Melioidosis is endemic in Southeast Asia and northern Australia and can resemble various conditions. Soft tissue involvement is usually limited to localise

1 January 2026 in Critical Care Research and Practice
Verified
Journal Article
Open access
TUNG PHI NGUYENTUNG PHI NGUYEN
TUNG PHI NGUYEN
TKThang Trong Khong
Thang Trong Khong
HVHoai Thi Thu Vu
Hoai Thi Thu Vu
NNNam Ngoc Phuong Nguyen
Nam Ngoc Phuong Nguyen
PPPhong Van Phan
Phong Van Phan
PHPhuong Khanh Nguyen Hoang
Phuong Khanh Nguyen Hoang
Background: Persistent severe acute kidney injury (PS‐AKI)—recently standardized as Kidney Disease: Improving Global Outcomes (KDIGO) Stage 3 persisting ≥ 72 h, or renal replacement therapy/death after Stage 3 diagnosis—has emerged as a trajectory‐based phenotype complementing conventional KDIGO staging. Evidence in contemporary intensive care unit (ICU) cohorts remains limited. Methods: We retrospectively studied adults admitted to a tertiary ICU (January 2024–June 2025). Acute kidney injury (AKI) was staged per KDIGO 2012, with trajectories classified as Stage 1 AKI, transient AKI (Stage 2‐3 resolving within 48 h), persistent mild–moderate AKI, or PS‐AKI. The primary outcome was in‐hospital mortality; secondary outcomes included renal recovery. Predictors of PS‐AKI were explored using logistic regression and gradient boosting with SHAP attribution. Results: Among 139 ICU patients with AKI screened, 106 met criteria. Most AKI was community‐acquired (97/106, 91.5%). PS‐AKI accounted for 23% (24/106) and carried the worst outcomes, with in‐hospital mortality 54% and renal recovery 17%. Within Stage 2‐3, PS‐AKI was associated with substantially worse outcomes than non‐PS trajectories (mortality 54% vs 10.8%; adjusted HR for death 2.23, 95% CI 0.69–7.21; adjusted OR for renal recovery 0.07, 95% CI 0.01–0.24). A 72‐h landmark analysis showed similar but nonsignificant trends. Inflammatory profiles distinguished PS‐AKI, with higher neutrophil‐to‐lymphocyte ratio (NLR), C‐reactive protein (CRP), and lower platelets. The composite NLR‐to‐platelet ratio (NLR/PLT) was independently associated with PS‐AKI (adjusted OR 2.51 per doubling, 95% CI 1.52–4.12; AUC 0.86), while the systemic immune‐inflammation index (SII) showed no significant association. Conclusions: In this predominant community‐acquired ICU cohort, PS‐AKI was common and strongly associated with poor in‐hospital outcomes. The co‐occurrence of inflammation and thrombocytopenia, summarized by NLR/PLT, may represent a simple exploratory signal for early‐risk appraisal. These findings support further research into trajectory‐based AKI phenotypes and the potential utility of inflammation–hematologic markers in predicting persistence.

1 January 2025 in Case Reports in Critical Care
Verified
Journal Article
Open access
TUNG PHI NGUYENTUNG PHI NGUYEN
TUNG PHI NGUYEN
TKThang Trong Khong
Thang Trong Khong
TTTuan Duc Tran
Tuan Duc Tran
Hyperammonemic encephalopathy is a rare but serious condition often linked to hepatic dysfunction or metabolic disorders. Thyroid storm is an endocrine emergency that can cause profound metabolic disturbances, though its relationship with hyperammonemia remains unclear. We report a unique case of a 33‐year‐old previously healthy male who developed progressive fatigue, nausea, and vomiting, followed by acute neurological deterioration. Initial evaluation revealed hyperammonemia (284 μ mol/L) and thyrotoxicosis (fT4: 27 pmol/L and TSH: 0.007 μ IU/mL), with no hepatic dysfunction. His neurological status declined from GCS 12 to GCS 7 within hours. Brain MRI and cerebrospinal fluid analysis were unremarkable. The patient was diagnosed with coma in the setting of hyperammonemic encephalopathy and thyroid storm. Management included propylthiouracil, Lugol’s iodine, propranolol, hydrocortisone, and continuous renal replacement therapy (CRRT). His ammonia levels significantly improved within 48 h, leading to rapid clinical improvement and extubation. This case highlights the importance of recognizing hyperammonemia as a potential cause of altered mental status, even in the absence of hepatic dysfunction, and raises questions about potential but unestablished links between thyroid dysfunction and ammonia metabolism.